MedTrace Logo

Lutronic LaseMD for Treatment of Benign Pigmented Lesions

NCT03409952 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-03-13

No results posted yet for this study

Summary

The Lutronic LaseMD Laser System will be evaluated for the treatment of benign pigmented lesions.

Conditions

  • Benign Pigmented Lesions

Interventions

DEVICE

LaseMD and DUAL 1927nm Laser

Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.

DEVICE

LaseMD

Laser treatment of benign pigmented lesion using optimized treatment settings.

Sponsors & Collaborators

  • LUTRONIC Corporation

    lead INDUSTRY

Principal Investigators

  • Kari Larson, MBA · Sponsor GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-17
Primary Completion
2018-12-20
Completion
2019-02-25
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03409952 on ClinicalTrials.gov